Functional deficiencies of components of the MHC class I antigen pathway in human tumors of epithelial origin.
about
KRAS Mutant Pancreatic Cancer: No Lone Path to an Effective TreatmentRAS oncogenes: weaving a tumorigenic webIdentification of E2F1 as an important transcription factor for the regulation of tapasin expression.TAP1 down-regulation in primary melanoma lesions: an independent marker of poor prognosis.Molecular Approach to Uterine Leiomyosarcoma: LMP2-Deficient Mice as an Animal Model of Spontaneous Uterine Leiomyosarcoma.Characterization of signaling function and expression of HLA class I molecules in medulloblastoma.Involvement of proteasome β1i subunit, LMP2, on development of uterin leiomyosarcma.Augmentation of effects of interferon-stimulated genes by reversal of epigenetic silencing: potential application to melanoma.Mice-lacking LMP2, immuno-proteasome subunit, as an animal model of spontaneous uterine leiomyosarcoma.A novel role of HLA class I in the pathology of medulloblastomaMedulloblasoma: challenges for effective immunotherapy.Ovarian cancer molecular pathology.Neutrophil elastase enhances antigen presentation by upregulating human leukocyte antigen class I expression on tumor cells.Antigen processing and immune regulation in the response to tumours.Exposure to Melan-A/MART-126-35 tumor epitope specific CD8(+)T cells reveals immune escape by affecting the ubiquitin-proteasome system (UPS)Killing of non-Hodgkin lymphoma cells by autologous CD19 engineered T cells.Therapeutic Potential of Immunoproteasome Inhibition in Duchenne Muscular Dystrophy.Pathways accessory to proteasomal proteolysis are less efficient in major histocompatibility complex class I antigen production.MHC class I antigen processing pathway defects, ras mutations and disease stage in colorectal carcinoma.Immunotherapy in pancreatic ductal adenocarcinoma: an emerging entity?Long-term freedom from recurrence in 2 stage IV melanoma patients following vaccination with tyrosinase peptides.Immune Checkpoint Inhibition for Pancreatic Ductal Adenocarcinoma: Current Limitations and Future Options
P2860
Q26751520-76B902D9-F409-4803-ABFA-F79CE751E1E9Q28250360-1C338FD7-6DA6-43DB-B2E6-C26744412999Q30318613-FEF178A1-3182-4F4B-A7D8-25B3A332A5EDQ32159956-4D1BF3F2-EFBF-4B18-875C-6AD2D7A2AD2BQ34700785-AB0C67F7-90FC-4CC4-BD9D-48D92CE123BDQ34993398-24D15E19-448F-4FA0-BA1A-1D77F439FDE7Q35731556-8E5CE3AB-FF25-4DAD-BF13-097CCD2DE8D6Q36906147-E24CF004-E12C-441B-A987-9E62F1E78CA1Q36922697-F80B9BBB-0E09-4E0F-99EF-E3B1F762115AQ37272662-157237B2-C479-4F4F-8169-A79DFF38BF16Q37968929-46FBF0D8-A0E6-40C9-8284-60D353CF0461Q38021356-DAD388AA-9AF6-4557-A046-E24CF641809DQ38774373-4C4490D8-CDF0-4606-90C8-D337510023A2Q38818628-18687250-3D7B-4617-8B85-140822AE8E9AQ39796576-B541CCEA-6F65-48F4-AF14-BE86BA52D5A7Q40432901-6B8CA27C-8D13-476D-88BC-FA0A3C63A194Q42859444-BA1573EB-25DE-4259-B4D2-BCDB1BBE2874Q44253376-0B6BD729-A499-4ACF-B33E-EFB4376EA9E5Q44747139-A28C66D7-C259-4C2B-A5B3-0E95CE685622Q47568391-E06BA64A-10C6-4B17-88B6-E0F0845FA175Q48614800-793CFCFA-54D6-439F-8EBC-B524A04B70DCQ56890107-D24142B3-9E0C-4E13-8446-90A05196CEE9
P2860
Functional deficiencies of components of the MHC class I antigen pathway in human tumors of epithelial origin.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
2000年论文
@zh
2000年论文
@zh-cn
name
Functional deficiencies of com ...... n tumors of epithelial origin.
@en
type
label
Functional deficiencies of com ...... n tumors of epithelial origin.
@en
prefLabel
Functional deficiencies of com ...... n tumors of epithelial origin.
@en
P2093
P356
P1476
Functional deficiencies of com ...... n tumors of epithelial origin.
@en
P2093
P2888
P304
P356
10.1038/SJ.BMT.1702363
P407
P478
25 Suppl 2
P577
2000-05-01T00:00:00Z
P5875
P6179
1022092153